protagenic.com (PTIX) - שיעור רווח גולמי

Protagenic Therapeutics (PTIX) competes in the obesity and stress treatment niche, monetizing its patents. The gross margin ratio in the GURU.Markets chart data sequence demonstrates stability, with the indicator settling at 0.00. Business resilience is bolstered by adherence to testing ethics and biosafety, as well as the outsourcing of preclinical trials to external laboratories while maintaining full control over its own molecules.
פילוחים אנליטיים ודוחות נתונים של חברת Protagenic (PTIX)

Institutional capital evaluates Protagenic Therapeutics (PTIX) based on the efficiency of managing direct development costs. The average gross margin reflects the profit share after deducting the cost of goods sold, demonstrating how the robotization of protein analysis reduces operational personnel expenses. The stability of this metric confirms the scalability of the business model and the fundamental resilience of the asset within the neurodegenerative disease sector.